Actionable news
0
All posts from Actionable news
Actionable news in DEPO: Depomed, Inc.,

Additional definitive proxy soliciting materials filed by non-management and Rule 14(a)(12) material

BGCOLOR="WHITE">

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 14A

(RULE 14a-101)

SCHEDULE 14A INFORMATION

Proxy Statement Pursuant to Section 14(a) of the

Securities Exchange Act of 1934

Filed by the Registrant ¨ Filed by a Party other than the Registrant x

Check the appropriate box:

DEPOMED, INC.

(Name of Registrant as Specified in Its Charter)

HORIZON PHARMA PUBLIC LIMITED COMPANY

HORIZON PHARMA, INC.

(Name of Persons(s) Filing Proxy Statement, if Other Than the Registrant)

Payment of Filing Fee (Check the appropriate box):

Filed pursuant to Rule 14a-6

of the Securities Exchange Act of 1934, as amended

Filing by: Horizon Pharma Public Limited Company

Subject Company: Depomed, Inc.

SEC File No. of Depomed, Inc.: 001-13111

Horizon Pharma plc (Horizon Pharma) has filed a definitive proxy statement with the Securities and Exchange Commission and accompanying WHITE and BLUE proxy cards to be used to solicit requests that Depomed, Inc. (Depomed) call two related special meetings of shareholders.

This Schedule 14A filing consists of the following press release issued by Horizon Pharma on October 7, 2015 that contains information regarding Horizon Pharmas solicitation of requests that Depomed call two related special meetings of shareholders.

Horizon Pharma plc Announces That Three of the Leading Proxy Advisory Firms Recommend that Depomed Shareholders Provide Consent FOR the Special Meetings Requests

Proposals to be Considered at the Special Meetings Would Include Removal and Replacement of Entire Depomed Board of Directors and Repeal of Depomeds Recently Adopted Bylaw Amendments

DUBLIN, IRELAND October 7, 2015 Horizon Pharma plc (NASDAQ: HZNP) (Horizon Pharma), a biopharmaceutical company focused on improving patients lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, today commented on Proxy Mosaics (Proxy Mosaic) recommendation in support of Horizon Pharmas efforts to call two related special meetings of Depomed shareholders to remove and replace all of the current Depomed, Inc. (Depomed) directors and to repeal a series of recent amendments to Depomeds bylaws.

Proxy Mosaic recommended that shareholders of Depomed PROVIDE CONSENT FOR Horizon Pharmas solicitation for the calling of the special meetings by submitting their WHITE and BLUE proxy cards to Horizon Pharmas proxy solicitor, MacKenzie Partners, Inc. Proxy Mosaic is the third proxy advisory service to make that recommendation. Horizon Pharma previously announced that Glass Lewis & Co. and Institutional Shareholder Services had recommended that Depomed shareholders should provide such consent.

In its published report, Proxy Mosaic concluded that:

As expected, Proxy Mosaic did not at this juncture take a position on how shareholders should vote on Horizons proposals to remove the current Depomed directors, to elect Horizon Pharma nominees to replace them upon removal and to repeal a series of recent amendments to Depomeds bylaws at the special meetings, if called.

Horizon Pharmas solicitation statement for calling the two related special meetings and the letter to Depomed shareholders from Horizon Pharma describing the reasons Depomed shareholders should support the solicitation to call the special meetings, along with the documents related to Horizon Pharmas exchange offer for all of the outstanding shares of Depomed common stock, are viewable at: www.HorizonAndDepomed.com, a website that Horizon Pharma launched to provide details and other relevant information regarding its proposals for the special meetings and its proposed acquisition of Depomed via the exchange offer.

Connaught House, 1st Floor, 1 Burlington Road, Dublin 4, D04 C5Y6 , Ireland

About Horizon Pharma plc

Horizon Pharma plc is a biopharmaceutical company focused on improving patients lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. Horizon Pharma markets seven medicines through its orphan, primary care and specialty business units. Horizon Pharmas global headquarters are in Dublin, Ireland. For more information, please visit www.horizonpharma.com. Follow @HZNPplc on Twitter or view careers on our LinkedIn page.

Forward-Looking Statements

This press release contains forward-looking statements, including, but not limited to, statements related to Horizon Pharmas offer to exchange its ordinary shares for all issued and outstanding shares of Depomeds stock and the potential strategic and financial benefits thereof, the future financial performance and prospects of each of Horizon Pharma and Depomed, Horizon Pharmas business strategy and plans, and other statements that are not historical facts. These forward-looking statements are based on Horizon Pharmas current expectations and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which...


More